Assetmark Inc. Has $1.15 Million Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Assetmark Inc. boosted its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 5.9% in the third quarter, HoldingsChannel reports. The firm owned 80,982 shares of the company’s stock after buying an additional 4,500 shares during the period. Assetmark Inc.’s holdings in Takeda Pharmaceutical were worth $1,152,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. EverSource Wealth Advisors LLC grew its stake in shares of Takeda Pharmaceutical by 38.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock valued at $43,000 after buying an additional 859 shares during the period. Headlands Technologies LLC acquired a new stake in Takeda Pharmaceutical in the second quarter valued at approximately $59,000. Hexagon Capital Partners LLC increased its holdings in shares of Takeda Pharmaceutical by 34.3% during the third quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock valued at $63,000 after acquiring an additional 1,129 shares in the last quarter. Blue Trust Inc. raised its position in shares of Takeda Pharmaceutical by 74.0% during the second quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock worth $76,000 after purchasing an additional 2,330 shares during the period. Finally, Ridgewood Investments LLC bought a new position in shares of Takeda Pharmaceutical in the 2nd quarter worth $89,000. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Stock Performance

Shares of TAK stock opened at $13.57 on Friday. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64. The firm has a fifty day simple moving average of $14.29 and a two-hundred day simple moving average of $13.82. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.08. The firm has a market capitalization of $43.16 billion, a PE ratio of 23.60, a price-to-earnings-growth ratio of 0.26 and a beta of 0.54.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.